Download video

No Patient Left Behind: Equity in Liver Transplantation

No views

Alberta Transplant Institute

1 day ago

No Patient Left Behind: Equity in Liver Transplantation

No Patient Left Behind: Equity in Liver Transplantation

No Patient Left Behind: Equity in Liver Transplantation
50:27
No Patient Left Behind: Equity in Liver Transplantation
by Alberta Transplant Institute
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
12:45
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
by OncBrothers: Practice-Changing Cancer Discussions
Novel Approaches to Post-Transplant Graft Assessment with Biosensors and Biomarkers
1:05:10
Novel Approaches to Post-Transplant Graft Assessment with Biosensors and Biomarkers
by Alberta Transplant Institute
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
0:40
Real-world efficacy of second-line cabozantinib in renal cell carcinoma
by VJOncology
The HER2 Diagnostic and Treatment Landscape in NSCLC
18:37
The HER2 Diagnostic and Treatment Landscape in NSCLC
by OncBrothers: Practice-Changing Cancer Discussions
Case #2: Treating a Patient with Stage IV NSCLC with EGFR - 2025 Case Based Panel Discussions
31:07
Case #2: Treating a Patient with Stage IV NSCLC with EGFR - 2025 Case Based Panel Discussions
by Global Resource for Advancing Cancer Education
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
0:52
Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials
by VJHemOnc – Video Journal of Hematology \& HemOnc
Balancing Life as an RN with 2 jobs🩺
31:48
Balancing Life as an RN with 2 jobs🩺
by thenurselife242
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment
2:20
FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment
by OncologyTube
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
8:33
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
by GU Oncology Now
SGLT2 inhibitors in ADPKD: where are we?
8:58
SGLT2 inhibitors in ADPKD: where are we?
by Nefropapers
2L treatment for pancreatic cancer: limited data, clinical variables, future biomarkers
0:52
2L treatment for pancreatic cancer: limited data, clinical variables, future biomarkers
by VJOncology
Thursday, October 23rd
3:28:04
Thursday, October 23rd
by TBPN
S2 Episode 2: Should All Newly Diagnosed Multiple Myeloma Patients Be Treated With a Quadruplet i...
23:30
S2 Episode 2: Should All Newly Diagnosed Multiple Myeloma Patients Be Treated With a Quadruplet i...
by Medscape
BXCL701 plus pembrolizumab in 2L advanced PDAC
0:59
BXCL701 plus pembrolizumab in 2L advanced PDAC
by VJOncology
Early results from EVEREST-2 of A2B694, a CAR T therapy, in solid tumors
0:39
Early results from EVEREST-2 of A2B694, a CAR T therapy, in solid tumors
by VJOncology
Poolbeg Pharma kicks off POLB001 Phase 2a trial with specialist partner
5:57
Poolbeg Pharma kicks off POLB001 Phase 2a trial with specialist partner
by Proactive Investors
LPN\/Rt Laparoscopic partial nephrectomy #20251001#laparoscopicsurgeon
59:04
LPN\/Rt Laparoscopic partial nephrectomy #20251001#laparoscopicsurgeon
by Joeee
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
by VJOncology
Groesbeck man no longer in need of transplant after 'miraculous' recovery
1:35
Groesbeck man no longer in need of transplant after 'miraculous' recovery
by KCENNews
Alliance A021901 | Lung Neuroendocrine Tumors
2:44
Alliance A021901 | Lung Neuroendocrine Tumors
by Alliance for Clinical Trials in Oncology